P. R. Shatskaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
P. R. Shatskaya has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Irina A. Zolotovskaya
Samara State Medical University
4 shared publications - Dmitriy Viktorovich Duplyakov
FSBEI HE «Samara State Medical University» of the Ministry of Healthcare of the Russian Federation; SBHI «V. P. Polyakov Samara Regional Clinical Cardiology Dispensary
3 shared publications - Olesya Anatolievna Rubanenko
Samara State Medical University
3 shared publications - I. A. Zolotovskaya
Samara State Medical University
2 shared publications A. S. Salasyuk
Volgograd State Medical University
1 shared publication- Arina Ilinichna Sizova
Samara State Medical University
1 shared publication
Latest Publications
- Open Access
- 15 August 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (7) , 4662
Chronic kidney disease and coronary artery disease: risk stratification
Currently, the search for reliable biomarkers that combine high sensitivity and specificity and allow for the accurate diagnosis of chronic kidney disease (CKD) in patients with coronary artery disease (CAD) remains a key challenge in modern medicine. This study presents a systematic review of the current literature on the relationship between CKD and CAD, with a focus on risk stratification and the diagnostic value of specific biomarkers. The search was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and included the following databases: PubMed, Scopus, Web of Science, Google Scholar, CyberLeninka, eLibrary, and Clinical Trials. The quality of the selected publications was assessed using the Newcastle-Ottawa Scale for cohort studies and AMSTAR 2 for systematic reviews and meta-analyses. This literature review allowed us to systematize current data on the relationship between CKD and CAD and evaluate the role of key biomarkers in risk stratification in this patient population. The combination of these conditions creates a unique pathophysiological profile that requires special attention in both diagnosis and treatment. Biomarkers that require emphasis for more accurate risk stratification are described. This review demonstrated that CKD is an independent and powerful predictor of adverse outcomes after MI, stenting, and coronary artery bypass grafting. It is shown that therapy in this patient population requires an individualized approach.
- 15 August 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (7) , 4662
Open AccessChronic kidney disease and coronary artery disease: risk stratification
Currently, the search for reliable biomarkers that combine high sensitivity and specificity and allow for the accurate diagnosis of chronic kidney disease (CKD) in patients with coronary artery disease (CAD) remains a key challenge in modern medicine. This study presents a systematic review of the current literature on the relationship between CKD and CAD, with a focus on risk stratification and the diagnostic value of specific biomarkers. The search was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and included the following databases: PubMed, Scopus, Web of Science, Google Scholar, CyberLeninka, eLibrary, and Clinical Trials. The quality of the selected publications was assessed using the Newcastle-Ottawa Scale for cohort studies and AMSTAR 2 for systematic reviews and meta-analyses. This literature review allowed us to systematize current data on the relationship between CKD and CAD and evaluate the role of key biomarkers in risk stratification in this patient population. The combination of these conditions creates a unique pathophysiological profile that requires special attention in both diagnosis and treatment. Biomarkers that require emphasis for more accurate risk stratification are described. This review demonstrated that CKD is an independent and powerful predictor of adverse outcomes after MI, stenting, and coronary artery bypass grafting. It is shown that therapy in this patient population requires an individualized approach.
- 5 August 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (7)
Hepatocardial syndrome in patients after ST-segment elevation myocardial infarction. GEFEST study
Objective. To investigate the clinical and laboratory changes, specifically focusing on liver function tests, echocardiographic parameters, as well as cognitive and emotional status, and to assess the incidence of cardiovascular events over a period of 12 months in elderly patients diagnosed with hepatocardial syndrome after ST-elevation myocardial infarction (STEMI), in the settings of standard cardiac therapy. Materials and methods. A prospective cohort comparative study was conducted, involving 537 patients aged 60 years or older (median age 68 [64; 73] years), who were evaluated no later than 6 months after a STEMI event. Two comparable groups were established through stratified selection based on sex, age, left ventricular ejection fraction (LVEF), and the grade of hepatic dysfunction: the main study group (n=269) and the control group (n=268). Patients in the main study group received ademetionine in addition to standard cardiac therapy, while those in the control group received standard therapy only. The primary endpoints included changes in alanine aminotransferase (ALAT), gamma-glutamyl transpeptidase (GGTP), and albumin levels at 6 months. Secondary endpoints included changes in LVEF, validated questionnaires scores (Montreal Cognitive Assessment Scale, Hospital Anxiety and Depression Scale, and Multidimensional Assessment of Fatigue), and the frequency of recurrent myocardial infarction, stroke, and cardiovascular mortality within 12 months. Statistical analyses were performed using the t-test, Mann—Whitney test, Pearson’s χ² test, and Bonferroni-corrected Cox regression for primary outcomes (p<0.0167). Results. In the main study group, a significant decrease in ALT levels was observed at 6 months, with a reduction of 41.8% (from 56.8±16.4 to 33.1±11.6 U/L), and a decrease in GGTP by 49.6% (from 78.4±24.6 to 39.5±14.8 U/L); albumin levels increased by 17.2% (from 34.2±4.6 to 40.1±5.0 g/L). All changes were statistically significant (p0.05). The increase in LVEF in the main group was 4.4% (p<0.001), while the control group showed a minimal increase of 0.8% (p=0.068). The incidence of cardiovascular events within 12 months was 5.9% in the main group versus 12.7% in the control group (p=0.006). According to Cox regression analysis, ademetionine therapy was independently correlated with a reduced risk of cardiovascular events (HR=0.51; 95% CI 0.33—0.79; p<0.001). Conclusions. Among elderly patients who have experienced ST-segment elevation myocardial infarction, there are observable slight improvements in liver function tests and left ventricular ejection fraction following standard therapy. The use of ademetionine is associated with more pronounced improvements in laboratory, instrumental, and clinical outcomes, warranting further investigation in randomized clinical trials.
- 5 August 2026
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (7)
Hepatocardial syndrome in patients after ST-segment elevation myocardial infarction. GEFEST study
Objective. To investigate the clinical and laboratory changes, specifically focusing on liver function tests, echocardiographic parameters, as well as cognitive and emotional status, and to assess the incidence of cardiovascular events over a period of 12 months in elderly patients diagnosed with hepatocardial syndrome after ST-elevation myocardial infarction (STEMI), in the settings of standard cardiac therapy. Materials and methods. A prospective cohort comparative study was conducted, involving 537 patients aged 60 years or older (median age 68 [64; 73] years), who were evaluated no later than 6 months after a STEMI event. Two comparable groups were established through stratified selection based on sex, age, left ventricular ejection fraction (LVEF), and the grade of hepatic dysfunction: the main study group (n=269) and the control group (n=268). Patients in the main study group received ademetionine in addition to standard cardiac therapy, while those in the control group received standard therapy only. The primary endpoints included changes in alanine aminotransferase (ALAT), gamma-glutamyl transpeptidase (GGTP), and albumin levels at 6 months. Secondary endpoints included changes in LVEF, validated questionnaires scores (Montreal Cognitive Assessment Scale, Hospital Anxiety and Depression Scale, and Multidimensional Assessment of Fatigue), and the frequency of recurrent myocardial infarction, stroke, and cardiovascular mortality within 12 months. Statistical analyses were performed using the t-test, Mann—Whitney test, Pearson’s χ² test, and Bonferroni-corrected Cox regression for primary outcomes (p<0.0167). Results. In the main study group, a significant decrease in ALT levels was observed at 6 months, with a reduction of 41.8% (from 56.8±16.4 to 33.1±11.6 U/L), and a decrease in GGTP by 49.6% (from 78.4±24.6 to 39.5±14.8 U/L); albumin levels increased by 17.2% (from 34.2±4.6 to 40.1±5.0 g/L). All changes were statistically significant (p0.05). The increase in LVEF in the main group was 4.4% (p<0.001), while the control group showed a minimal increase of 0.8% (p=0.068). The incidence of cardiovascular events within 12 months was 5.9% in the main group versus 12.7% in the control group (p=0.006). According to Cox regression analysis, ademetionine therapy was independently correlated with a reduced risk of cardiovascular events (HR=0.51; 95% CI 0.33—0.79; p<0.001). Conclusions. Among elderly patients who have experienced ST-segment elevation myocardial infarction, there are observable slight improvements in liver function tests and left ventricular ejection fraction following standard therapy. The use of ademetionine is associated with more pronounced improvements in laboratory, instrumental, and clinical outcomes, warranting further investigation in randomized clinical trials.
- 22 April 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (2S)
Using artificial intelligence technologies for phenotyping and optimization of combination lipid-lowering therapy in elderly patients with atherosclerosis (PHOENIX Study)
Aim . To evaluate the potential of artificial intelligence (AI) technologies as a "second pilot" tool for phenotyping elderly patients with atherosclerosis in various vascular systems and to study the clinical efficacy of combination lipid-lowering therapy (rosuvastatin + ezetimibe) in this population. Material and methods. This prospective cohort study included 739 patients over 60 years of age (median, 67 [63; 72] years; women, 52,8%) with verified atherosclerosis (coronary, cerebral, or peripheral arteries). Using stratified randomization, patients were divided into two following groups: the main group (n=371) received combination therapy (rosuvastatin 20 mg + ezetimibe 10 mg/day) for 6 months; the control group (n=368) received standard lipid-lowering therapy (rosuvastatin 20 mg/day) in accordance with clinical guidelines. A machine learning algorithm (gradient boosting with SHAP-based interpretation) integrated into the clinical decision support system was used for patient phenotyping. Lipid profile, echocardiographic parameters, and changes in comorbid pathology were assessed at the baseline visit and after 3and 6-month follow-up. R e sults . The AI algorithm allowed us to identify four following clinical phenotypes of patients with atherosclerosis: "coronary" (38,2%), "cerebrovascular" (27,6%), "multifocal" (19,1%), and "metabolic" (15,1%). In the study group, significant lipid profile improvement was recorded by the 6th month of follow-up as follows: a 54,2% decrease in low-density lipoprotein cholesterol (LDL-C) (pConclusion . The use of AI as a "second pilot" allows for therapeutic strategy personalization in elderly patients with atherosclerosis. Combination therapy with rosuvastatin and ezetimibe demonstrates high efficacy in achieving target lipid levels and positive dynamics in echocardiographic parameters, with the greatest effect in certain clinical phenotypes.
- 22 April 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (2S)
Using artificial intelligence technologies for phenotyping and optimization of combination lipid-lowering therapy in elderly patients with atherosclerosis (PHOENIX Study)
Aim . To evaluate the potential of artificial intelligence (AI) technologies as a "second pilot" tool for phenotyping elderly patients with atherosclerosis in various vascular systems and to study the clinical efficacy of combination lipid-lowering therapy (rosuvastatin + ezetimibe) in this population. Material and methods. This prospective cohort study included 739 patients over 60 years of age (median, 67 [63; 72] years; women, 52,8%) with verified atherosclerosis (coronary, cerebral, or peripheral arteries). Using stratified randomization, patients were divided into two following groups: the main group (n=371) received combination therapy (rosuvastatin 20 mg + ezetimibe 10 mg/day) for 6 months; the control group (n=368) received standard lipid-lowering therapy (rosuvastatin 20 mg/day) in accordance with clinical guidelines. A machine learning algorithm (gradient boosting with SHAP-based interpretation) integrated into the clinical decision support system was used for patient phenotyping. Lipid profile, echocardiographic parameters, and changes in comorbid pathology were assessed at the baseline visit and after 3and 6-month follow-up. R e sults . The AI algorithm allowed us to identify four following clinical phenotypes of patients with atherosclerosis: "coronary" (38,2%), "cerebrovascular" (27,6%), "multifocal" (19,1%), and "metabolic" (15,1%). In the study group, significant lipid profile improvement was recorded by the 6th month of follow-up as follows: a 54,2% decrease in low-density lipoprotein cholesterol (LDL-C) (pConclusion . The use of AI as a "second pilot" allows for therapeutic strategy personalization in elderly patients with atherosclerosis. Combination therapy with rosuvastatin and ezetimibe demonstrates high efficacy in achieving target lipid levels and positive dynamics in echocardiographic parameters, with the greatest effect in certain clinical phenotypes.
- Open Access
- 10 November 2025
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Science and Innovations in Medicine
- Vol. 10 (4) , 290-296
Gender and age effects on coronary calcium index in patients with suspected CHD
Aim – to assess the influence of sex and age on the coronary artery calcium (CAC) score in patients with suspected coronary heart disease (CHD). Material and methods. A prospective, observational, single-center study was conducted. The study included 733 patients (mean age 67 [58; 73] years, 43.37% male) with suspected CHD who underwent multi-slice computed tomography (MSCT) of the coronary arteries with CAC scoring (using the Agatston method), as well as a biochemical blood test assessing lipid profile, glucose level, creatinine level, and estimated glomerular filtration rate (eGFR). An analysis of baseline clinical and laboratory parameters and the distribution of CAC scores according to patient age and sex was performed. Statistical analysis was performed using SPSS Statistics 21.0, employing the Shapiro-Wilk test, Student’s t-test, and ANOVA. Results. It was found that CAC scores increased with advancing age, and men had significantly higher CAC scores than women of the same age category. In the group of patients with higher CAC scores, older men were more prevalent, and there were higher creatinine levels and a higher incidence of atrial fibrillation. The correlation analysis revealed moderate and strong associations between CAC scores and parameters of lipid metabolism, as well as eGFR. Conclusion. The assessment of CAC scores, taking into account sex and age, improves the accuracy of cardiovascular risk stratification in patients with suspected CHD. The implementation of this approach into clinical practice helps optimize preventive and therapeutic strategies for reducing cardiovascular morbidity and mortality.
- 10 November 2025
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Science and Innovations in Medicine
- Vol. 10 (4) , 290-296
Open AccessGender and age effects on coronary calcium index in patients with suspected CHD
Aim – to assess the influence of sex and age on the coronary artery calcium (CAC) score in patients with suspected coronary heart disease (CHD). Material and methods. A prospective, observational, single-center study was conducted. The study included 733 patients (mean age 67 [58; 73] years, 43.37% male) with suspected CHD who underwent multi-slice computed tomography (MSCT) of the coronary arteries with CAC scoring (using the Agatston method), as well as a biochemical blood test assessing lipid profile, glucose level, creatinine level, and estimated glomerular filtration rate (eGFR). An analysis of baseline clinical and laboratory parameters and the distribution of CAC scores according to patient age and sex was performed. Statistical analysis was performed using SPSS Statistics 21.0, employing the Shapiro-Wilk test, Student’s t-test, and ANOVA. Results. It was found that CAC scores increased with advancing age, and men had significantly higher CAC scores than women of the same age category. In the group of patients with higher CAC scores, older men were more prevalent, and there were higher creatinine levels and a higher incidence of atrial fibrillation. The correlation analysis revealed moderate and strong associations between CAC scores and parameters of lipid metabolism, as well as eGFR. Conclusion. The assessment of CAC scores, taking into account sex and age, improves the accuracy of cardiovascular risk stratification in patients with suspected CHD. The implementation of this approach into clinical practice helps optimize preventive and therapeutic strategies for reducing cardiovascular morbidity and mortality.
- Open Access
- 20 April 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (3) , 4361
D-dimer as a risk factor for cardiovascular events in patients with liver diseases
The relationship between cardiovascular and liver diseases is a significant clinical problem; since diseases of one system can aggravate the other. One of the key markers for cardiovascular risk assessment in patients with liver diseases is D-dimer. This is a fibrin degradation product; the level of which increases with the coagulation system activation. It is important to note the role of ademetionine (Heptral®) in supporting liver function; reducing inflammation and oxidative stress; which can reduce the development and progression of atherosclerosis and cardiovascular complications in patients with liver disease. Determination of D-dimer is important in risk stratification and assessment of clinical outcomes in patients with liver and cardiovascular comorbidity; including those treated with ademetionine.
- 20 April 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (3) , 4361
Open AccessD-dimer as a risk factor for cardiovascular events in patients with liver diseases
The relationship between cardiovascular and liver diseases is a significant clinical problem; since diseases of one system can aggravate the other. One of the key markers for cardiovascular risk assessment in patients with liver diseases is D-dimer. This is a fibrin degradation product; the level of which increases with the coagulation system activation. It is important to note the role of ademetionine (Heptral®) in supporting liver function; reducing inflammation and oxidative stress; which can reduce the development and progression of atherosclerosis and cardiovascular complications in patients with liver disease. Determination of D-dimer is important in risk stratification and assessment of clinical outcomes in patients with liver and cardiovascular comorbidity; including those treated with ademetionine.
- Open Access
- 6 July 2022
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 18 (3) , 282-288
Lipid profile of patients with arterial hypertension who underwent COVID-19: possibilities of drug therapy/ LEADER
Aim.To study the dynamics of the lipid profile of hypertensive patients with dyslipidemia who underwent COVID-19.Material and methods. Hypertensive patients with dyslipidemia who underwent COVID-19 [n=126; 58 men and 68 women; median age 60 (56.0; 65.5) years] examined. Patients were included into two groups: group 1 (n=64) received a single pill combination of lisinopril + amlodipine + rosuvastatin; 2 groups (n=62) continued the previous drug treatment. Clinical, demographic, office blood pressure (BP), total cholesterol (TC), low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol, triglycerides, C-reactive protein (CRP) levels were assessed in all patients in 3 visits within 24 weeks.Results.The groups did not differ in prior antihypertensive therapy (except for more frequent use of angiotensin II receptor blockers in group 2, pConclusion.The single pill combination of lisinopril/amlodipine/rosuvastatin in hypertensive patients with dyslipidemia who underwent COVID-19 led to an improvement in lipid profile and blood pressure control.
- 6 July 2022
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 18 (3) , 282-288
Open AccessLipid profile of patients with arterial hypertension who underwent COVID-19: possibilities of drug therapy/ LEADER
Aim.To study the dynamics of the lipid profile of hypertensive patients with dyslipidemia who underwent COVID-19.Material and methods. Hypertensive patients with dyslipidemia who underwent COVID-19 [n=126; 58 men and 68 women; median age 60 (56.0; 65.5) years] examined. Patients were included into two groups: group 1 (n=64) received a single pill combination of lisinopril + amlodipine + rosuvastatin; 2 groups (n=62) continued the previous drug treatment. Clinical, demographic, office blood pressure (BP), total cholesterol (TC), low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol, triglycerides, C-reactive protein (CRP) levels were assessed in all patients in 3 visits within 24 weeks.Results.The groups did not differ in prior antihypertensive therapy (except for more frequent use of angiotensin II receptor blockers in group 2, pConclusion.The single pill combination of lisinopril/amlodipine/rosuvastatin in hypertensive patients with dyslipidemia who underwent COVID-19 led to an improvement in lipid profile and blood pressure control.